Retatrutide, a newer triple agonist targeting GIP, GLP-1, and glucagon receptors, has a half-life of approximately six days
Yes, generally, individuals with Type 2 diabetes can donate plasma as long as their diabetes is well-managed and under control
Through coordinated GLP-1R and GIPR activation, tirzepatide enhances glucose-dependent insulin secretion, improves glycemic control, contributes to lipid homeostasis, and reduces appetite and food intake, supporting its clinical use in obesity and type 2 diabetes [13]
Shop by Health Benefits Discover our doctor-formulated products collections designed to provide targeted nutritional support for your longevity, optimal health and energy management